samedan logo

 
 
spacer
home > ebr > autumn 2019 > pet technology and tumour progression
PUBLICATIONS
European Biopharmaceutical Review

PET Technology and Tumour Progression




Positron emission tomography (PET) is a widely used imaging technique in nuclear medicine for both clinical diagnostics and preclinical applications. PET enables 3D functional imaging using radioactive tracers (radiotracers), highlighting the spatial distribution of biomolecular activity in the bodies of animal models and humans. In this context, PET imaging is increasingly being used by researchers in drug development as it provides data that can be extrapolated from animal to human studies. Small animal imaging deepens our understanding of disease development and the effect of potential treatments, advances in PET technology are powering the translation of this research into the clinical setting.

The numerous types of tumours including those not yet well characterised and their unpredictable reactions to treatment make the search for new effective cancer therapies incredibly challenging. Non-invasive in vivo imaging technologies such as PET allow researchers to better understand the course of tumour development by visualising cancer-related processes in real time. Such methods are enabling researchers to further their knowledge of tumour morphology, progression, and biomarker expression. PET is able to provide information on the expression of receptors, energy metabolism, and other biomarkers of tumours by imaging an intravenously injected radiotracer. This radiotracer comprised a radioisotope, most commonly fluorine-18 (18F), attached to a molecular probe that targets a specific molecule or metabolic pathway, and its uptake by tumour cells is monitored.

The combination of other imaging modalities, such as magnetic resonance imaging (MRI), computed tomography (CT), and single-photon emission computed tomography (SPECT), joins structural and functional imaging in one experiment. PET/CT, PET/MRI, and PET/SPECT/CT multimodal systems are able to provide quantitative 3D tomographic images of radiotracers, bone, and soft tissue, furthering the growing knowledge of cancer biology and treatment.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Todd Sasser is Head of Applications for Bruker Preclinical Imaging. Todd works directly with research sites involved in PET applications across a wide variety of disciplines from infection imaging and cancer biology to probe development. He studied at the University of Liverpool, UK, and The University of Hawaii, US, and was a visiting scholar at The University of Notre Dame, France.
spacer
Dr Todd Sasser
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement